PFT PULMONARY FUNCTION TEST at Dr. Essa Lab

PFT PULMONARY FUNCTION TEST at Dr. Essa Lab

The PFT PULMONARY FUNCTION TEST at Dr. Essa Lab is a comprehensive, non-invasive diagnostic assessment designed to evaluate the functional capacity of the respiratory system. This specialized suite of tests measures how well the lungs inhale and exhale air, how efficiently they transfer oxygen into the bloodstream, and how effectively they clear carbon dioxide from the body. Performed utilizing state-of-the-art spirometers and plethysmography equipment, this test serves as a cornerstone in modern pulmonology for diagnosing, staging, and monitoring a wide spectrum of respiratory disorders. Dr. Essa Laboratory & Diagnostic Centre, a pioneer in diagnostic excellence in Pakistan since 1987, offers this advanced physiological evaluation across its premier facilities in Karachi and other major cities, ensuring patients receive highly accurate, clinically validated results.

At its core, the pulmonary function test evaluates several critical aspects of lung mechanics. It measures lung volumes, capacities, rates of flow, and gas exchange. The primary technology employed is spirometry, which records the volume of air an individual can inhale or exhale as a function of time. In more comprehensive clinical scenarios, plethysmography (body box testing) is utilized to measure static lung volumes, such as Residual Volume (RV) and Total Lung Capacity (TLC), which cannot be measured by standard spirometry alone. Additionally, diffusing capacity tests (DLCO) may be integrated to assess the integrity of the alveolar-capillary membrane. Understanding these physiological parameters is vital because structural changes in the airways, lung parenchyma, or thoracic cage directly alter these measurements, providing clinicians with a functional map of the patient's respiratory health.

The clinical importance of the PFT PULMONARY FUNCTION TEST cannot be overstated. It is the gold standard for differentiating between obstructive lung diseases (such as asthma and chronic obstructive pulmonary disease) and restrictive lung diseases (such as idiopathic pulmonary fibrosis or chest wall deformities). Furthermore, it provides invaluable prognostic information, helps assess surgical risk for patients undergoing major thoracic or abdominal procedures, and monitors the therapeutic efficacy of bronchodilators, inhaled corticosteroids, and other respiratory interventions. By choosing Dr. Essa Lab, patients benefit from a highly standardized testing environment, overseen by experienced technologists and interpreted by expert consultant physicians, ensuring the highest standards of diagnostic accuracy and patient care.

Clinical Procedure: What to Expect

Patient Preparation

Proper patient preparation is absolutely critical to obtaining accurate, reproducible, and clinically useful results during a PFT PULMONARY FUNCTION TEST. Because the test measures maximum respiratory effort and airway reactivity, patients must strictly adhere to the following preparation guidelines:

• Avoid Bronchodilators: Patients must withhold specific asthma or COPD medications prior to the test, as these can mask underlying airway obstruction. Short-acting bronchodilators (e.g., Albuterol, Salbutamol) should typically be avoided for 4 to 6 hours before the test. Long-acting bronchodilators (e.g., Salmeterol, Formoterol) should be withheld for 12 to 24 hours, and ultra-long-acting medications may require up to 36 to 48 hours of cessation. Always consult with your referring physician before altering your medication schedule.
• No Smoking or Vaping: Patients must refrain from smoking tobacco, using e-cigarettes, or inhaling any recreational substances for at least 24 hours prior to the test, as nicotine and smoke inhalation cause acute bronchoconstriction and alter airway resistance.
• Avoid Heavy Meals: Do not eat a heavy meal for at least 2 hours before the test. A full stomach can physically restrict diaphragmatic excursion, preventing full lung expansion and leading to artificially reduced lung volumes.
• Avoid Caffeine: Refrain from consuming coffee, tea, energy drinks, cola, or chocolate for at least 4 hours before the procedure, as caffeine possesses mild bronchodilatory properties that can skew test results.
• Wear Loose Clothing: Wear comfortable, loose-fitting clothing that does not restrict the chest or abdomen, allowing for maximum inhalation and forceful exhalation.
• Avoid Vigorous Exercise: Do not engage in strenuous physical activity or intense exercise for at least 2 to 3 hours prior to the test to ensure your respiratory rate and airway tone are at baseline.
• Postpone if Recently Ill: If you have had a recent respiratory infection, cold, flu, or acute bronchitis within the last 3 to 4 weeks, inform the laboratory, as temporary airway hyperresponsiveness can affect the baseline results.

During the Procedure

The PFT PULMONARY FUNCTION TEST is performed in a dedicated, climate-controlled diagnostic room to ensure equipment calibration remains stable. The procedure is guided step-by-step by a highly trained respiratory technician who will coach you through various breathing maneuvers to ensure maximum effort and accuracy.

To begin, you will sit upright in a comfortable chair. The technician will place a soft, comfortable clip on your nose to prevent air from escaping through your nostrils, ensuring that all inhaled and exhaled air passes exclusively through the testing device. You will then be instructed to place a sterile, disposable mouthpiece connected to the spirometer into your mouth. It is essential to form a tight, complete seal with your lips around the mouthpiece to prevent any air leaks during the breathing cycles.

The technician will first ask you to breathe normally to establish a baseline. You will then be instructed to take the deepest breath possible, filling your lungs completely to Total Lung Capacity (TLC). Once your lungs are fully expanded, the technician will direct you to blast the air out into the mouthpiece as hard, fast, and completely as you possibly can. You must continue blowing out forcefully for at least 6 seconds (or until your lungs are completely empty) even when you feel you have no air left. This forced expiratory maneuver is repeated at least three times to ensure reproducibility and consistency, meeting the strict guidelines established by the American Thoracic Society (ATS).

In many clinical cases, a post-bronchodilator test is performed. After completing the initial baseline spirometry, you will be given a few puffs of a quick-acting bronchodilator inhaler (such as Salbutamol). You will rest quietly for approximately 15 minutes to allow the medication to relax your airway smooth muscles. After this waiting period, the forced breathing maneuvers are repeated. This allows clinicians to determine if your airway obstruction is reversible, a key diagnostic indicator for asthma. The entire procedure is completely safe, non-invasive, and typically takes between 30 to 45 minutes. Some patients may experience mild lightheadedness or transient coughing during the forced exhalation, which is entirely normal and resolves quickly with brief rest.

When is a PFT PULMONARY FUNCTION TEST Performed?

Asthma Evaluation and Monitoring

Physicians frequently request a PFT PULMONARY FUNCTION TEST when a patient exhibits symptoms suggestive of asthma, such as episodic wheezing, chest tightness, shortness of breath, or a chronic dry cough that worsens at night or during exercise. The test is crucial for confirming the diagnosis by demonstrating variable, reversible airflow limitation. By comparing the pre-bronchodilator and post-bronchodilator results, the test helps clinicians assess the degree of airway hyperresponsiveness. For patients already diagnosed with asthma, periodic PFTs are performed to monitor disease control, assess the effectiveness of controller medications, and adjust treatment plans to prevent severe asthma exacerbations.

Chronic Obstructive Pulmonary Disease (COPD)

A PFT is the definitive diagnostic tool for Chronic Obstructive Pulmonary Disease (COPD), which includes chronic bronchitis and emphysema. Physicians order this test for individuals with a history of chronic tobacco smoke exposure, occupational dust exposure, or progressive dyspnea on exertion. The test detects persistent, non-fully reversible airflow limitation (characterized by a post-bronchodilator FEV1/FVC ratio of less than 0.70). The results allow pulmonologists to grade the severity of COPD according to international GOLD guidelines, guide pharmacological therapy, determine the need for long-term oxygen therapy, and monitor the rate of lung function decline over time.

Unexplained Chronic Cough or Shortness of Breath

When a patient presents with persistent, unexplained shortness of breath (dyspnea) or a chronic cough lasting more than eight weeks that cannot be explained by common causes like gastroesophageal reflux or post-nasal drip, a PFT is indicated. The test helps differentiate whether the underlying cause is pulmonary, cardiac, or neuromuscular. By evaluating lung volumes and gas exchange capacity, the test can point toward early-stage interstitial lung disease, pulmonary vascular disease, or chest wall restrictions, providing a clear diagnostic pathway when standard chest X-rays appear normal.

Pre-Operative Surgical Risk Assessment

Prior to undergoing major cardiothoracic, upper abdominal, or prolonged general surgeries, patients—especially those with a history of smoking, obesity, advanced age, or known respiratory disease—frequently undergo a PFT. Surgeons and anesthesiologists utilize these results to evaluate the patient's pulmonary reserve and assess the risk of post-operative pulmonary complications, such as respiratory failure, atelectasis, or prolonged mechanical ventilation. The test helps optimize the patient's lung function pre-operatively and guides post-operative respiratory therapy and mobilization strategies.

Occupational and Environmental Exposure Monitoring

Individuals who work in environments with high exposure to respiratory hazards—such as silica, asbestos, coal dust, chemical fumes, mold, or organic dusts—require regular PFT monitoring. Physicians utilize these tests to screen for early signs of occupational lung diseases like pneumoconiosis, asbestosis, or occupational asthma before symptoms become severe or irreversible. Regular surveillance allows for timely intervention, such as workplace modifications, personal protective equipment optimization, or reassignment, to prevent permanent, debilitating parenchymal lung damage.

What Does a PFT PULMONARY FUNCTION TEST Detect?

The PFT PULMONARY FUNCTION TEST is an incredibly sensitive diagnostic tool capable of detecting a wide array of physiological abnormalities, structural impairments, and specific respiratory conditions. By analyzing the flow rates, lung volumes, and response to bronchodilators, the test can detect and characterize the following clinical findings:

• Reversible Airway Obstruction: Characterized by a significant improvement in FEV1 or FVC (typically >12% and >200 mL) after bronchodilator administration, highly indicative of bronchial asthma.
• Fixed (Irreversible) Airway Obstruction: Persistent reduction in expiratory flow rates despite bronchodilator therapy, characteristic of Chronic Obstructive Pulmonary Disease (COPD).
• Restrictive Lung Pattern: Suggested by a reduction in Forced Vital Capacity (FVC) with a normal or elevated FEV1/FVC ratio, indicating reduced lung compliance or chest expansion.
• Intrinsic Restrictive Lung Disease: Parenchymal disorders such as Idiopathic Pulmonary Fibrosis (IPF), sarcoidosis, or drug-induced lung toxicity that scar lung tissue.
• Extrinsic Restrictive Lung Disease: Non-parenchymal disorders affecting the chest wall, pleura, or respiratory muscles, such as severe kyphoscoliosis, pleural effusion, or morbid obesity.
• Mixed Obstructive-Restrictive Pattern: A complex physiological impairment showing features of both airflow limitation and reduced lung volumes, often seen in patients with overlapping COPD and pulmonary fibrosis.
• Air Trapping: An abnormal increase in Residual Volume (RV) and the RV/TLC ratio, indicating that air remains trapped in the lungs at the end of a forced exhalation, commonly seen in severe emphysema.
• Lung Hyperinflation: An abnormal elevation of Total Lung Capacity (TLC) and Functional Residual Capacity (FRC), resulting from chronic loss of lung elastic recoil in emphysematous disease.
• Small Airway Disease: Early-stage obstruction in the peripheral airways, often detected via abnormalities in the mid-expiratory flow rate (FEF 25-75%).
• Impaired Gas Exchange (Reduced DLCO): A decrease in the diffusing capacity of the lung, indicating damage to the alveolar-capillary membrane, commonly caused by emphysema, interstitial lung disease, or pulmonary hypertension.
• Normal Gas Exchange with Restriction: A normal DLCO in the presence of a restrictive pattern, pointing toward extrapulmonary causes of restriction, such as neuromuscular weakness or chest wall deformities.
• Respiratory Muscle Weakness: Reduced maximal inspiratory and expiratory pressures, indicating weakness of the diaphragm or intercostal muscles due to conditions like Amyotrophic Lateral Sclerosis (ALS), Myasthenia Gravis, or Guillain-Barré syndrome.
• Fixed Upper Airway Obstruction: Characterized by a flattened inspiratory and expiratory loop on the flow-volume curve, indicating a structural narrowing of the trachea or larynx (e.g., tracheal stenosis, goiter).
• Variable Extrathoracic Obstruction: Indicated by a flattened inspiratory loop with a preserved expiratory loop, often associated with vocal cord dysfunction or laryngospasm.
• Variable Intrathoracic Obstruction: Indicated by a flattened expiratory loop with a preserved inspiratory loop, suggesting localized tumors or tracheomalacia within the thoracic cavity.
• Loss of Lung Elastic Recoil: Highly compliant lungs that easily expand but fail to empty efficiently, a classic physiological hallmark of emphysema.
• Pulmonary Congestion: Alterations in diffusing capacity and lung volumes secondary to chronic fluid accumulation in the lung parenchyma, often associated with congestive heart failure.
• Early-stage Asbestosis or Silicosis: Subtle restrictive changes and decreased diffusing capacity in individuals with a history of mineral dust exposure.
• Surgical Ineligibility: Severely compromised lung function (e.g., FEV1 < 800 mL or <30% of predicted value) that indicates an unacceptably high risk for major lung resection surgery.
• Therapeutic Unresponsiveness: Lack of improvement in flow rates over time, indicating that current anti-inflammatory or bronchodilator therapies are insufficient or that the disease has progressed to a fibrotic stage.

Turnaround Time and Report Access at Dr. Essa Lab

At Dr. Essa Lab, we understand that timely diagnostic results are essential for prompt clinical decision-making and patient peace of mind. The raw data from your PFT PULMONARY FUNCTION TEST is captured digitally by our advanced diagnostic software immediately upon completion of the breathing maneuvers. This data is then meticulously reviewed, quality-checked, and interpreted by our consultant pulmonologists or specialized physicians to ensure clinical accuracy.

The finalized, comprehensive diagnostic report is typically available within 24 to 48 hours of your test. Dr. Essa Lab offers multiple convenient ways to access your reports. Patients can visit any of our conveniently located collection centers in Karachi and nationwide to collect a high-quality printed report. Alternatively, you can access, view, and download your digital report directly from the secure online portal on the official Dr. Essa Lab website or via our dedicated mobile application. This seamless digital integration ensures that you and your referring physician can review the results promptly, facilitating rapid treatment planning and continuous care monitoring.

PFT PULMONARY FUNCTION TEST Findings Overview

The following table outlines the key parameters evaluated during a standard pulmonary function test, comparing normal physiological ranges with potential abnormal findings and their clinical implications:

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Forced Vital Capacity (FVC)	≥ 80% of predicted value based on age, sex, height, and ethnicity.	< 80% of predicted value; indicates restriction (e.g., pulmonary fibrosis, obesity) or severe air trapping.
Forced Expiratory Volume in 1 Second (FEV1)	≥ 80% of predicted value; reflects overall flow in large and medium airways.	< 80% of predicted value; indicates airway obstruction (e.g., asthma, COPD) or severe restriction.
FEV1/FVC Ratio	≥ 70% to 80% (or above the Lower Limit of Normal – LLN) in adults.	< 70% (or below LLN); the definitive hallmark of obstructive airway disease (COPD, asthma).
Peak Expiratory Flow (PEF)	80% to 100% of personal best or predicted value; measures maximum speed of expiration.	< 80% of predicted; indicates acute bronchoconstriction, asthma exacerbation, or poor effort.
Forced Expiratory Flow (FEF 25-75%)	60% to 120% of predicted value; measures flow in the medium and small airways.	< 60% of predicted; suggests early small airway disease or mild obstructive impairment.
Total Lung Capacity (TLC)	80% to 120% of predicted value; measured via plethysmography.	< 80% indicates restrictive lung disease; > 120% indicates pulmonary hyperinflation (emphysema).
Residual Volume (RV)	80% to 120% of predicted value; volume of air remaining after maximal exhalation.	> 120% indicates significant air trapping, typical of severe obstructive lung disease.
Diffusing Capacity (DLCO)	≥ 80% of predicted value; measures gas transfer across the alveolar membrane.	< 80% indicates alveolar-capillary destruction (emphysema, interstitial lung disease, pulmonary hypertension).

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Dr. Essa Lab for PFT PULMONARY FUNCTION TEST?

• Experienced Healthcare Professionals: Our pulmonary function tests are conducted by highly trained, certified respiratory technologists and interpreted by expert consultant pulmonologists.
• Patient-Focused Care: We prioritize patient comfort, safety, and clear communication, ensuring a stress-free diagnostic experience from start to finish.
• Quality Diagnostic Services: Dr. Essa Lab adheres to stringent international quality control guidelines, ensuring highly reproducible and clinically reliable test results.
• Professional Reporting: We provide detailed, comprehensive, and easy-to-read diagnostic reports that clearly outline key respiratory parameters and clinical interpretations.
• Modern Diagnostic Approach: Our laboratories are equipped with advanced, calibrated spirometers and diagnostic software that meet the latest American Thoracic Society (ATS) standards.
• Comfortable Environment: Our dedicated testing rooms are designed to provide a clean, hygienic, and highly comfortable setting for patients of all ages.
• Convenient Location: With an extensive network of branches across Karachi and other major cities, accessing premium diagnostic care is highly convenient for patients nationwide.
• Commitment to Accurate Diagnosis: Since 1987, Dr. Essa Lab has maintained an unwavering commitment to diagnostic integrity, accuracy, and clinical excellence, making us a trusted partner in your healthcare journey.